

1 **Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan**
2 **Africa: A systematic review and meta-analysis.**

3 Esther M Nasuuna ^{1,2}, Nicholus Nanyenya ³, Davis Kibirige ^{1,4}, Jonathan Izudi^{2,5}, Chido Dziva
4 Chikwari ^{6,7} Robert Kalyesubula ^{1,8}, Barbara Castelnovo², Laurie A Tomlinson ⁹, Helen A Weiss⁷.

5 *1 Noncommunicable Diseases Program, Medical Research Council/Uganda Virus Research Institute*
6 *and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe Uganda*

7 *2 Infectious Diseases Institute, Makerere University, College of Health Sciences, Kampala, Uganda.*

8 *3 Department of Epidemiology and Biostatistics, School of Public Health, Makerere University*
9 *College of Health Sciences, Kampala, Uganda*

10 *4 Department of Medicine, Uganda Martyrs Hospital Lubaga, Kampala Uganda.*

11 *5 Department of Community Health, Mbarara University of Science and Technology, Uganda.*

12 *6 Biomedical Research and Training Institute, Harare, Zimbabwe*

13 *7 MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical*
14 *Medicine, London, UK*

15 *8 Departments of Physiology and Medicine, Makerere University College of Health Sciences,*
16 *Kampala, Uganda*

17 *9 Department of non-Communicable Disease Epidemiology, London School of Hygiene and Tropical*
18 *Medicine, Keppel Street, London, WC1E 7HT, UK*

19

20 **Corresponding author**

21 **Esther. M. Nasuuna**

22 Email; enasuuna@idi.co.ug (EN)

23

24

Abstract

25 **Background.**

26 Globally, the prevalence of chronic kidney disease (CKD) is increasing among young people living
27 with HIV (YPLHIV), with inconsistent estimates. Aggregated data on the prevalence of CKD are
28 needed in sub-Saharan Africa (SSA) to inform strategies for early diagnosis and management. We
29 conducted a systematic review and meta-analysis to estimate the pooled prevalence of CKD among
30 YPLHIV in SSA.

31 **Methods.**

32 We searched Medline/PubMed, EMBASE, African Index Medicus, and African Journals Online for
33 articles reporting the prevalence of CKD among YPLHIV in SSA using predefined search strategies
34 up to 15th January 2024. The reference lists of identified articles were checked for additional eligible
35 studies. The eligibility criteria were studies among YPHLIV aged 10-24 years reporting CKD
36 prevalence defined by either glomerular filtration rate (GFR), albumin-to-creatinine ratio (ACR) or
37 proteinuria. We used a narrative synthesis to report differences between the included studies. The
38 DerSimonian-Liard random effects model was used to pool the CKD prevalence, and heterogeneity
39 was assessed using the Cochrane Q-test and I-squared values. We assessed the risk of bias in each
40 article using the Joanna Briggs Institute checklist and publication bias in a funnel plot and Egger's
41 test.

42 **Results.**

43 Of 802 retrieved articles, 16 fulfilled the eligibility criteria and were included in the meta-analysis. Of
44 these, 13 (86.7%) were cross-sectional studies that used estimated GFR to diagnose CKD. Only two
45 studies followed the standard definition of CKD. The pooled CKD prevalence was 12.1% (95% CI
46 6.5-19.2%), ranging from 0.8% to 53.1% according to the definition used, with a high degree of
47 heterogeneity ($I^2=97.5\%$, $p<0.001$). The included studies were of moderate quality, with no evidence
48 of publication bias. Sensitivity analysis showed that the findings were robust to the methodological
49 and analytic approach.

50 **Conclusion.**

51 CKD prevalence among YPLHIV is moderately high and highly heterogeneous across SSA. The
52 standard definition of CKD should be used to enable estimation of CKD prevalence in different
53 studies and settings. HIV programs enrolling YPLHIV should routinely screen for CKD to ensure
54 early diagnosis and management.

55 **PROSPERO registration number:** CRD42022347588.

56

57 **Keywords:** Chronic kidney disease, young people living with HIV, Sub-Saharan Africa, prevalence

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77 **Introduction**

78 In 2022, an estimated 3.4 million young people (15-24 years) and 1.7 million adolescents (10-19
79 years) were living with human immunodeficiency virus (HIV) globally, of whom approximately 80%
80 lived in sub-Saharan Africa (SSA) (1-3). The number of young people living with HIV (YPLHIV) in
81 SSA is increasing due to increased infant survival (4-6). Among children living with HIV, there has
82 been a 10-fold reduction in mortality and improved survival since 2004 largely due to the scale-up of
83 antiretroviral therapy (ART) (4). As a result, infants who acquire HIV perinatally survive into
84 adulthood and develop comorbidities such as chronic kidney disease (CKD), cardiovascular diseases,
85 and type 2 diabetes (7, 8). These comorbidities affect almost all body systems and have important
86 implications for HIV treatment, quality of life, and survival (6, 9).

87

88 CKD is becoming more prevalent globally and is projected to be the fifth leading cause of mortality
89 globally by 2040 (10, 11). In both adults and children, CKD is defined by Kidney Disease Improving
90 Global Outcomes (KDIGO) as a glomerular filtration rate (GFR) $<60\text{ml}/\text{min}/1.73\text{m}^2$ and/or the
91 presence of markers of kidney damage for three or more months (12, 13). GFR can be estimated
92 (eGFR) using a biomarker and one of the estimating equations or measured (mGFR) using
93 compounds such as Iohexol (14-16). Markers of kidney damage include structural abnormalities seen
94 on imaging (changes in kidney size and increased echogenicity), histology, electrolyte disorders
95 (hyperkalaemia, phosphaturia), urine sediment abnormalities, proteinuria, and albuminuria (12). The
96 Global Burden of Disease study (2017) estimates the prevalence of CKD at 9.1% (95% confidence
97 interval (CI) 8.5-9.8%) globally (17), varying by region: 6.0-17.0% in the United States, 7.0-34.3% in
98 Asia, and 3.3-17.3% in Europe (60-62). The rising prevalence of CKD in high-income countries is
99 partially attributed to the increasing incidence of diabetes mellitus and hypertension (18), while in
100 several low- and middle-income countries (LMICs), HIV and Hepatitis C are the major contributing
101 factors (19).

102

103 Among people living with HIV, the kidney is affected by direct HIV infection of the renal epithelial
104 cells, deposition of immune complexes, and toxicities from drugs used to treat HIV (Tenofovir

105 Disoproxil Fumarate (TDF), protease inhibitors, or HIV-related opportunistic infections (amphotericin
106 B) (20-22). Although ART initiation is protective against kidney diseases, especially HIV-associated
107 nephropathy (23), there is evidence of increased prevalence of kidney diseases after ART initiation
108 (24-26). CKD is among the 10 most common non-infectious complications of HIV in the US (20, 27).
109
110 YPLHIV are at an increased risk for CKD compared to those without HIV (28). Young people who
111 acquire HIV through vertical transmission have a higher risk of CKD compared to other young people
112 without HIV or those infected later in life, due to chronic HIV infection of an immature kidney, long-
113 term ART exposure, and drug toxicities (29). CKD is particularly difficult to estimate in young people
114 due to dependence on eGFR using serum creatinine which is influenced by muscle mass that changes
115 with age and nutritional status (30, 31). Creatinine levels in children are also harder to measure as
116 they are lower than those in adults and require a highly sensitive test (32). Other reasons for
117 underestimation of CKD prevalence are a lack of surveillance and poor measurement and reporting of
118 CKD (29, 33). CKD prevalence reported from several observational studies in SSA is inconsistent.
119 We conducted the first systematic review and meta-analysis to determine the pooled prevalence of
120 CKD among YPLHIV in SSA and to understand the reasons for possible heterogeneity in the
121 prevalence.

122

123 **Methods**

124 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 2020
125 was used to guide the systematic review (Appendix 1) (34). The study protocol (Appendix 2) was
126 registered with Prospective Register of Systematic Reviews (PROSPERO) and was assigned the
127 registration number CRD42022347588.

128

129 **Eligibility criteria**

130 Inclusion criteria were manuscripts published in any year reporting the prevalence of CKD using any
131 predefined definition that shows kidney damage or kidney injury, including the Kidney Disease
132 Improving Global Outcomes (KDIGO) definitions (Box 1), among YPLHIV in any of the sub-
133 Saharan African countries, whose population had a mean or median age between 10 and 24 years. We
134 excluded case-control studies, case series, case reports, conference abstracts without accompanying
135 manuscripts, and studies of low quality (those that scored less than 50% on assessment). The outcome
136 of interest was the prevalence of CKD computed as a proportion with a 95% CI. The diagnosis of

Box 1: KDIGO CKD Definition.

CKD KDIGO definition: GFR <60 ml/min per 1.73m² or markers of kidney damage for >3 months. Markers of kidney damage: Albumin creatinine ratio (ACR) >30mg/g, Protein creatinine ratio (PCR) >150mg/g (11).

Five stages of chronic kidney disease

Stage 1 with normal or high GFR (GFR > 90 mL/min)

Stage 2 Mild CKD (GFR = 60-89 mL/min)

Stage 3A Moderate CKD (GFR = 45-59 mL/min)

Stage 3B Moderate CKD (GFR = 30-44 mL/min)

Stage 4 Severe CKD (GFR = 15-29 mL/min)

Stage 5 End Stage CKD (GFR <15 mL/min)

<https://www.davita.com/education/kidney-disease/stages>

137 CKD could be based on either estimated or measured GFR, or an albumin creatinine ratio (ACR)
138 ≥ 30 mg/g or proteinuria.

139

140 **Information sources and search strategy**

141 The main search was conducted on 30th June 2022 with an update on 15th January 2024. We searched
142 four databases (Medline via PubMed, EMBASE, African Index Medicus, and African Journals
143 Online) for eligible articles without restrictions on the year of publication or language. Search terms
144 were developed for each database, including Medical Subject Heading (MESH) terms and keywords
145 (Appendix 3). Search terms included i) chronic kidney diseases, kidney diseases, renal diseases, renal
146 insufficiency, proteinuria, albuminuria); ii) HIV, human immunodeficiency virus; iii) young people,
147 young adults, adolescents, and paediatric; and iv) Africa, SSA, sub-Saharan Africa, Africa south of
148 the Sahara, and individual SSA countries. Reference lists from eligible articles were searched for

149 further relevant articles. A citation search was conducted in the Web of Science to identify other
150 relevant articles.

151 **Study selection and data collection.**

152 Two reviewers (EMN and JI) conducted the database searches and extracted all potentially relevant
153 articles to Endnote 20 (Clarivate, Philadelphia PA). Duplicated articles as determined by title, authors,
154 and journal name were excluded and the remaining articles were uploaded to Rayyan software
155 (<https://www.rayyan.ai/>) for further de-duplication and screening (35). Three reviewers (EMN, NN,
156 and DK) independently screened all the articles by title and abstract according to the eligibility
157 criteria. A full-text search by two reviewers (EMN and NN) was conducted to identify articles that
158 fulfilled the eligibility criteria. Two studies published in languages other than English were translated
159 online before review. Discrepancies were resolved by discussion and consensus among all reviewers.
160 If consensus could not be reached, the decision was made by the third senior reviewer (DK).
161 Reference lists and articles citing the included articles were reviewed using Web of Science to
162 identify any relevant articles that had been missed during the database search.

163

164 **Data abstraction**

165 EMN performed the initial data abstraction in a Microsoft Excel sheet according to a predetermined
166 data abstraction tool, which was verified by NN for completeness and accuracy. The data abstracted
167 included the first author's name, country of origin, population, inclusion and exclusion criteria,
168 demographic characteristics such as age and sex, sample size, number of participants with CKD,
169 country, region of SSA (Eastern, Western, Central, and Southern), disease definition, equation used,
170 diagnosis, whether or not the diagnosis was confirmed after the required three months, and any
171 comorbidities.

172

173 **Study quality assessment.**

174 The Joanna Briggs Institute (JBI) checklist for prevalence studies was used to assess the quality of the
175 included studies (36). A decision to include, exclude, or seek further information was reached for each
176 of the studies. A study was considered low quality if it scored less than 50%, moderate quality if it

177 scored between 50 and 70% and high quality if it scored above 70% (37). Low quality studies were to
178 be excluded as per the eligibility criteria.

179 **Data analysis**

180 Statistical analysis was performed in STATA statistical software version 17 (College Station, TX).
181 The Microsoft Excel sheet containing the data items was imported into STATA for analysis. Pooled
182 CKD prevalence was calculated by performing a meta-analysis of proportions using the DerSimonian-
183 Liard random-effects model allowing for generalised linear mixed models with logit link to account
184 for the within study uncertainties (38). CKD prevalences were displayed in a forest plot. Evidence for
185 the presence of heterogeneity was determined using the Cochrane Q test and quantified using I^2
186 values. If the degree of heterogeneity was above 50%, the studies were considered heterogeneous;
187 otherwise, they were considered non heterogenous (39). We extended the same model to assess the
188 source of heterogeneity in a sub-group analysis to determine if the pooled prevalence differed by
189 region, definition of CKD used, sample size, whether or not the measurements were repeated or
190 sampling strategy. Furthermore, we performed meta-regression analysis to determine the source of the
191 observed statistical heterogeneity (40). A funnel plot and Egger's test were used to assess for
192 publication bias (41). We interpreted a symmetrical funnel plot as suggestive of no publication bias
193 and an asymmetrical one as indicating publication bias. To distinguish between publication bias and
194 small study effect, we performed a contour-enhanced funnel plot. If publication bias was confirmed,
195 we performed a trim and fill analysis. A sensitivity analysis was conducted using the leave-one-out
196 Jackknife method to determine the robustness of the study findings to the analytic approach (42).

197
198 The narrative synthesis framework was used to report the differences between the studies. This was
199 based on the Institute of Medicine standards for qualitative synthesis in systematic reviews (43).
200 Specifically, the methodological characteristics such as sample size, participant inclusion and
201 exclusion criteria, strengths and limitations of each study, potential bias, and patterns across the
202 studies were all reported (43).

203 **Results**

204 **Study selection.**

205 We retrieved a total of 802 articles that fulfilled the inclusion criteria and excluded 198 duplicates.
206 These studies were published between 1990 and 2023. After screening the remaining 604 articles by
207 title and abstract, 120 were found to be potentially eligible. Eight of these were duplicates, and 4 had
208 inaccessible full texts, so 108 articles were retrieved for the full-text search. Of these, 92 were
209 excluded for the following reasons: 35 had an ineligible population, 34 did not have the prevalence
210 disaggregated by age for adults and young people, 20 were case-control studies or case reports and 3
211 were conference abstracts with no accompanying manuscript. Overall, 16 articles fulfilled the
212 inclusion criteria and were included in the meta-analysis (Figure 1).

213 *Figure 1 Flow Diagram showing the included studies.*

214

215 **Study characteristics.**

216 Table 1 summarises the characteristics of the 16 included studies. Details are provided in Appendix 4.
217 The studies reported information on 4,365 participants from 32 ART clinics in 14 SSA countries. Four
218 studies were from West Africa (44-47), five from East Africa (48-52), six from Southern Africa (6,
219 33, 53-56) and one from Central Africa (57). Eligible studies were conducted between 2013 and 2023.
220 Fourteen studies were cross-sectional (6, 33, 44-50, 52-57), with three nested within cohorts (6, 33,
221 51) and two were cohort studies (47, 51). Sample sizes ranged from 12-784 participants (median 237;
222 interquartile range 123-371). Only two studies reported sample size estimation and the assumptions
223 made (48, 55).

224 The mean or median age in each study was between 10 and 24 years, with an age range of 6-30 years.
225 The proportion of female participants in each study was 40-58%. Three studies recruited participants
226 who were ART-naïve (46, 47, 58), 11 studies recruited ART-experienced participants (6, 33, 44, 45,
227 48, 51-53, 55-57), and two studies recruited both ART-naïve and ART-experienced participants (49,
228 50). Three studies recruited only YPLHIV who were perinatally infected (6, 33, 51). Among the
229 studies that recruited ART-experienced participants, two included only those on TDF-containing

230 regimens (45, 53). Four studies enrolled HIV-negative control groups from the general population (6,
231 33, 56, 57).

232 ***Diagnosis of CKD***

233 Different methods were used to diagnose CKD. The most common biomarker used for CKD diagnosis
234 was serum creatinine measured by the enzymatic method. Estimated GFR (eGFR) was used in 13
235 studies alone and in combination with markers of kidney damage (6, 33, 44-47, 51-53, 55-58). Five
236 studies used an eGFR cut-off of $<60\text{ml}/\text{min}/1.73\text{m}^2$ (44-46, 55, 57), two used this cutoff alone without
237 any marker of kidney damage (45, 57) and six used a cut-off of $<90\text{ml}/\text{min}/1.73\text{m}^2$ (6, 33, 47, 51, 53,
238 58). These studies showed a CKD prevalence between 0.8% and 35.9%. The remaining studies used
239 albumin creatinine ratio (ACR) or microalbuminuria to diagnose CKD (49, 50, 56). These studies
240 used $\text{ACR} >20\text{mg}/\text{g}$ (49) or $\text{ACR} >30\text{ mg}/\text{g}$ (50) and a point of care test (56). Three studies used both
241 ACR and eGFR (33, 44, 57). Two studies used proteinuria on dipstick as one of the diagnostic criteria
242 on spot urine samples (54, 55). One study used Urinary Neutrophil Gelatinase-Associated Lipocalin
243 (UNGAL) for diagnosis and found a prevalence of 15.1% (48). No study used measured GFR or
244 mGFR to diagnose CKD. Only four studies repeated the tests to determine chronicity, at week 6 (49),
245 month 3 (55), month 6 (51), and after an average of four years (47). Equations used to estimate GFR
246 included modified Schwartz in six studies (6, 44, 45, 53, 55, 57), Modification of Diet in Renal
247 Disease (MDRD) in two studies (46, 51), and the full-age spectrum formula in two studies (58, 47).
248 The equation was not mentioned in the remaining three.

249 **Table 1 shows details of the included studies.**

250 *F: Female, ACR: Albumin creatinine ratio, ART: Antiretroviral therapy, eGFR: Estimated glomerular*
251 *filtration rate, IQR: Interquartile range, HIV: Human Immunodeficiency Virus, TDF: Tenofovir*
252 *Disoproxil Fumarate, UNGAL: Urine Neutrophil Gelatinase-Associated Lipocalin. NA: Not*
253 *applicable MDRD: Modification of Diet in Renal Disease*

254

255 **Synthesis of results**

256 The pooled CKD prevalence was 12.1% (95% CI 6.5-19.8%), ranging from 0.8% to 53.1%, and was
257 highly heterogeneous ($I^2=97.5\%$) (Figure 2). Subgroup analysis (Table 2) showed that the lowest
258 pooled CKD prevalence of 5.4% (95% CI 3.8-7.1%) was in two studies that used
259 eGFR<60ml/min/1.73m² to diagnose CKD. The highest pooled CKD prevalence was 27.6% (95% CI
260 15.7-40.6%) in the five studies that used nonprobability sampling techniques, but heterogeneity was
261 high ($I^2=89.0\%$).

262 **Assessment of heterogeneity**

263 Meta-regression analysis results are summarized in Table 3. In univariable meta-regression analysis,
264 studies that used probability sampling methods were highly heterogeneous compared to those that did
265 not mention the sampling strategy ($\beta=1.91$, 95% CI 0.82-2.99). The heterogeneity was lower among
266 studies that repeated the eGFR measurements to determine chronicity compared to studies that did not
267 repeat the measurements ($\beta=-1.93$, 95% CI -3.38, -0.48) and studies with a sample size above 300
268 participants compared to those with less than 100 participants ($\beta=-1.83$, 95% CI -3.40, -0.26). The
269 other variables were not statistically significant sources of the observed heterogeneity. In a
270 multivariable meta-regression analysis after adjusting for region, whether or not the measurements
271 were repeated, sampling strategy and the CKD definition used, only three variables accounted for the
272 observed statistical heterogeneity. Studies that repeated measurements for CKD were highly
273 heterogeneous compared to studies that did not repeat CKD measurements (adjusted $\beta= -1.09$; 95% CI
274 -2.18,-0.01, $p=0.05$), those that used probability sampling methods (adjusted $\beta= 2.05$; 95% CI 0.96,
275 3.13 $p=0.004$) as well as studies that used eGFR cut off as less than 90ml/min/1.73m² and albumin
276 creatinine ratio compared to the ones that used an eGFR cut off of 60ml./min/1.73m² (adjusted $\beta= -$
277 1.44 95% CI -2.76, -0.17 $p=0.03$) and (adjusted $\beta= -1.42$ 95% CI -2.76, -0.08 $p=0.04$) respectively.

278 **Table 2: Pooled prevalence of CKD and sources of heterogeneity in the sub-group analysis.**

Variable	No of studies	Sample size	Pooled prevalence (%) (95% CI*)	Heterogeneity I ² (p value)
Definition of CKD				
eGFR <60ml/min/1.73 m ²	4	1173	5.9 (3.6-8.7)	70.6 (0.02)
eGFR <90ml/min/1.73m ²	6	2055	11.11 (2.3-25.1)	98.5 (<0.001)
eGFR & proteinuria	3	390	26.9 (5.7-55.4)	97.5 (<0.001)
Albumin Creatinine Ratio	3	747	13.1 (6.5, 21.5)	85.2 (<0.001)
Measurements repeated				
Yes	3	1259	2.4 (0.6-5.3)	83.4 (<0.001)
No	13	3106	15.4 (8.7-23.6)	96.8 (<0.001)
Region				
East Africa	5	1498	13.2 (4.1-26.2)	97.1 (<0.001)
South Africa	6	1850	9.2 (2.6-19.1)	97.4 (<0.001)
West Africa	4	616	18.7 (2.5-43.7)	97.0 (<0.001)
Central Africa	1	401	6.5 (4.2-9.1)	-
Sample size				
<100	4	287	26.6 (10.9-45.9)	90.1 (<0.001)
100-300	6	1310	11.6 (4.5-21.2)	95.6 (<0.001)
>300	6	2768	6.7 (1.6-14.7)	97.9 (<0.001)
By publication year				
Before 2019	6	1244	19.9 (7.4-36.4)	97.1 (<0.001)
After 2019	10	3121	8.6 (3.9-14.8)	96.6 (<0.001)
ART status at enrolment				
ART naïve	3	644	19.6 (0.8-53.4)	98.7 (<0.001)
On ART	11	3305	8.3 (3.8-14.3)	96.2 (<0.001)
Both naïve and on ART	2	416	26.7 (3.8-32.8)	33.7 (0.22)
Sampling strategy				
Probability	7	965	25.9 (15.8-37.3)	92.2 (<0.001)
Nonprobability	4	1233	5.3 (1.9-10.2)	90.7 (<0.001)
Not mentioned	5	2167	5.2 (2.1-9.6)	93.2 (<0.001)

279 *CI confidence interval

280

281 **Table 3: Factors associated with CKD prevalence using univariable and multivariable meta-**
 282 **regression analysis findings.**

Variable	Univariable meta-regression analysis		Multivariable meta-regression analysis	
	Coefficient (95% CI*)	P value	Coefficient (95% CI*)	P value
Definition of CKD				
eGFR <60ml/min/1.73 m ²	0		0	
eGFR & proteinuria	1.72 (-0.37, 3.81)	0.09	0.12 (-1.14, 1.39)	0.81
eGFR <90ml/min/1.73m ²	0.34 (-1.38, 2.06)	0.67	-1.44 (-2.76, -0.17)	0.03
Albumin Creatinine Ratio	0.90 (-1.12, 2.93)	0.35	-1.42 (-2.76, -0.08)	0.04
Measurements repeated				
No	0		0	
Yes	-1.93 (-3.38, -0.48)	0.01	-1.09(-2.18, -0.01)	0.05
SSA Region				
Central Africa	0		0	
West Africa	1.02 (-2.25, 4.29)	0.51	0.27 (-1.51, 2.04)	0.73
East Africa	0.52 (-2.66, 3.71)	0.73	0.67 (-0.95, 2.28)	0.35
South Africa	0.18 (-2.96, 3.33)	0.90	1.61 (-0.22, 3.44)	0.08
Sample size				
<100	0		-	-
100-300	-1.09 (-2.66, 0.48)	0.16	-	-
>300	-1.83 (-3.40, -0.26)	0.03	-	-
Publication year				
Before 2019	0		-	-
After 2019	-1.05 (-2.37, 0.28)	0.11	-	-
ART status at enrolment				
Both naïve and on ART	0		-	-
On ART	-1.47 (-3.45, 1.78)	0.13	-	-
ART naïve	-0.57 (-2.92, 1.78)	0.61	-	-
Sampling strategy				
Not mentioned	0		0	0
Nonprobability	0.04 (-1.21, 1.28)	0.95	-0.98 (-2.09, 0.13)	0.07
Probability	1.91 (0.82, 2.99)	0.002	2.05 (0.96, 3.13)	0.004

283 CI confidence interval, CKD Chronic kidney disease, eGFR estimated glomerular filtration rate, SSA
 284 Sub Saharan Africa, ART Anti-retroviral therapy.
 285

286 Figure 2: Forest plot of studies reporting the prevalence of CKD among YPLHIV in SSA

287 *Publication Bias*

288 There was no evidence of publication bias as the funnel plot was symmetrical (Figure 3), and this was
 289 confirmed with Egger’s test (p=0.14).

290 Figure 3: Funnel plot of included studies.

291 **Risk of bias within and across studies**

292 Based on the JBI checklist (Table 4), all of the studies had an appropriate sample frame and sampling
 293 (n=16). Only five studies described the study setting and population appropriately. All studies used
 294 different criteria to diagnose CKD (Table 1), but the statistical analysis was appropriately performed
 295 (n=16). Since none of the studies scored less than 50%, all were included in the analysis.

296 **Table 4: Results of the bias assessment using the JBI Checklist.**

Author, year	Qn1*	Qn2	Qn3	Qn4	Qn5	Qn6	Qn7	Qn8	Qn9	Score	Overall appraisal
Diack, 2020	Yes	No	No	No	Yes	Yes	Yes	Yes	Yes	0.7	Include
Okafor, 2016	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	0.8	Include
Ekulu, 2019	Yes	No	No	No	Yes	Yes	Yes	No	Yes	0.6	Include
Frigati, 2019	Yes	No	No	No	Yes	Yes	Yes	Yes	Yes	0.7	Include
Frederick, 2016	Yes	Unk	Yes	No	Yes	No	Yes	Yes	Yes	0.7	Include
Frigati, 2018	Yes	Unk	Unk	No	Yes	Yes	Yes	Yes	Yes	0.7	Include
Iduoriyekemwen, 2013	Yes	Unk	Unk	No	Yes	Yes	Yes	Yes	Yes	0.7	Include
Mashingaidze-Mano, 2020	Yes	No	No	No	Yes	Yes	Yes	Yes	Yes	0.7	Include
Drak 2021	Yes	Unk	Unk	Yes	Yes	Yes	Yes	Yes	Yes	0.8	Include
Lomole, 2021	Yes	Yes	Unk	Yes	Yes	Yes	Yes	Yes	Yes	0.9	Include
Tadesse, 2018	Yes	Unk	Unk	Yes	Yes	Yes	Yes	Yes	Yes	0.8	Include
Mosten, 2015	Yes	Yes	Unk	No	Yes	Yes	Yes	Yes	Yes	0.8	Include
Zimba, 2015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1	Include
Bagoloire, 2023	Yes	Unk	Yes	Yes	Yes	Yes	No	Yes	Unk	0.7	Include
Areprekumor, 2023	Yes	No	Yes	Yes	Yes	No	No	Yes	Unk	0.6	Include
Byers, 2023	Yes	Unk	Unk	Yes	Yes	Yes	Yes	Yes	Unk	0.7	Include

297 *Unk Unknown *1. Was the sample frame appropriate to address the target population?2. Were study*
298 *participants sampled in an appropriate way?3. Was the sample size adequate?4. Were the study*
299 *subjects and the setting described in detail?5. Was the data analysis conducted with sufficient*
300 *coverage of the identified sample?6. Were valid methods used for the identification of the*
301 *condition?7. Was the condition measured in a standard, reliable way for all participants?8. Was there*
302 *appropriate statistical analysis?9. Was the response rate adequate, and if not, was the low response*
303 *rate managed appropriately?*

304 **Sensitivity analysis results**

305 Sensitivity analysis showed that pooled CKD prevalence fell within the 95% confidence interval of
306 the original pooled CKD prevalence when the leave-one-out Jackknife analysis was performed. This
307 suggests that the findings were robust to methodological and analytic approach and that no single
308 study had significant influence on the overall meta-analytic results.

309 **Discussion**

310 To our knowledge, this is the first systematic review and meta-analysis to systematically review CKD
311 prevalence among YPLHIV in sub-Saharan Africa. The pooled prevalence was 12.1%, ranging from
312 0.8% to 53% with considerable heterogeneity. Findings from subgroup analysis showed that the CKD
313 prevalence differed according to the study sample size, diagnostic definitions, laboratory methods, the
314 region, sampling strategy, and whether or not measurements were repeated to determine chronicity.
315 Only diagnostic definitions, sampling strategy and whether or not measurements were repeated
316 accounted for the observed heterogeneity.

317 There are very few papers that estimate CKD prevalence among YPLHIV in SSA. Systematic reviews
318 and studies on the prevalence of CKD in PLHIV in other settings have also found a variable
319 prevalence of 6 to 48% depending on the region and definitions used (59-62). In populations at
320 increased risk for CKD such as people living with diabetes, hypertension, sickle cell disease, and
321 PLHIV, a higher CKD prevalence has been reported (12). In our review, studies included PLHIV and
322 excluded participants with conditions known to cause CKD, such as hypertension, diabetes, sickle cell
323 disease, and hepatitis B and C (63). This ensured that any observed CKD was probably a result of the

324 various mechanisms by which HIV affects the kidneys, thus reflecting the prevalence of CKD in
325 YPLHIV.

326 KDIGO defines CKD as $GFR < 60 \text{ ml/min/1.73m}^2$ with or without markers of kidney damage for three
327 months or more (12) and this definition has been shown to improve diagnostic precision with
328 implications for management (64). However, only four studies fulfilled the chronicity criteria; three
329 studies repeated the tests after more than 3 months (47, 51, 55), and one study repeated the tests after
330 only one month (49). Three studies used a cut-off of $< 90 \text{ ml/min/1.73m}^2$ which does not fit the
331 KDIGO definition and tended to overestimate the CKD prevalence (6, 53, 54). Other studies used
332 ranges such as 60-90 or 30-60 ml/min/1.73m^2 potentially underestimating the CKD prevalence (45,
333 51). Albuminuria is known as an early marker of endothelial and kidney damage and might precede a
334 decrease in GFR in people with CKD (33). Varying cut-offs of albuminuria and proteinuria were also
335 used in the studies. Using these in isolation has limitations as several conditions (acute kidney injury,
336 febrile illness, and intense exercise) lead to transient proteinuria hence an overestimate of the CKD
337 prevalence (65). This limitation has also been mentioned in previous systematic reviews of CKD
338 prevalence in Africa among the general population and other high-risk groups (61). Two of the studies
339 with CKD prevalence exceeding 20% used albumin for CKD diagnosis (49, 50).

340 The most common biomarker used to estimate GFR was serum creatinine despite its limitations (66)
341 such as being affected by muscle mass, general nutritional status, exercise, and diet (31). Using
342 creatinine to estimate GFR has been shown to overestimate GFR, potentially underestimating CKD in
343 a large multicentre study conducted in Uganda, Malawi, and South Africa (67). Most studies used the
344 Jaffe method to measure serum creatinine which has also been shown to overestimate creatinine
345 clearance compared to the enzymatic method (61) leading to low CKD prevalence as diagnosed by
346 eGFR. Cystatin C has been reported as a better biomarker in Africa but is rarely used because it is
347 expensive (67) and none of the studies included used Cystatin C. Equations that use multiple markers
348 are also better at estimating GFR than those that use a single marker (68, 69) but all included studies
349 used a single marker. Further, none of the included studies measured GFR, yet it could have been
350 useful given the limitations of serum creatinine (70, 71).

351 Estimating equations such as the Modification of Diet in Renal Disease (MDRD), Chronic Kidney
352 Disease Epidemiology (CKD-EPI), and Cockcroft-Gault (CG) equations are frequently used to
353 estimate GFR (16). These equations have been validated in many diverse populations, but the
354 estimated GFR falls short of the measured GFR (66, 67, 70), and accuracy is worse when the
355 coefficients for race are added into the equation (70). A large multicentre study in Uganda, Malawi,
356 and South Africa found that none of the estimating equations they assessed, including the CKD-EPI
357 2021, gave a GFR that was within 30% of the measured GFR for more than 75% of the samples (67).
358 The review argued that there is an urgent need to find an affordable and sensitive biomarker to
359 overcome the current diagnostic inaccuracies (67, 71) and to develop an equation for African
360 populations (72).

361 Variability in CKD prevalence has also been reported in other populations across the world. Two
362 systematic reviews that determined the CKD prevalence in the general African population found a
363 prevalence similar to ours of 13.9% (95% CI 12.2-15.7) (19) but 2% to 41% in the general population
364 and 1% to 46% among PLHIV (61). In adults living with HIV, a systematic review and meta-analysis
365 across the globe found a pooled CKD prevalence of 6.4% (95% CI 5.2 to 7.7%), with high
366 heterogeneity (I^2 of 99.2% $p < 0.001$) that was explained by the World Health Organisation region (59).
367 Younger children living with HIV aged 1 to 18 years have a variable and high CKD prevalence as
368 well, ranging from 6.7% to 34.6% in African studies. A study in Zimbabwe among 220 ART-naïve
369 children aged 2-12 years found a CKD prevalence of 34.6% (95% CI 27.8-40.8%) using eGFR 30-
370 90ml/1.73m² (73). Children and adolescents aged 1 month to 18 years who were mostly ART naïve
371 (86%) have been found to have a microalbuminuria prevalence of 12% (95% CI 4.5-24.3%) in
372 Nigeria (74). Another Nigerian study involving 60 children who estimated GFR using cystatin C
373 found a CKD prevalence of 13.3% (95% CI 5.9-24.6%) with an eGFR cut-off of less than
374 60ml/min/1.73 m² (75).

375 **Strengths and limitations**

376 Our study has important strengths, such as being the first to systematically report on CKD prevalence
377 among YPLHIV in SSA, a lack of publication bias, findings being robust to the analytic approach and

378 methodology, and the search strategy being sensitive and comprehensive. Most of the studies did not
379 follow the standard definition of CKD and the diagnostic criteria was widely variable making it
380 difficult to produce a summary estimate. The other limitations was a lack of age disaggregation in the
381 reporting of the results in some studies that led to the exclusion of a few papers. Future research could
382 include contacting authors of concluded studies to re-analyse data and report age specific prevalence.

383 **Conclusions and recommendations**

384 The CKD prevalence among YPLHIV across SSA countries is moderately high and highly
385 heterogeneous. The use of standardized definitions and diagnostic methods is urgently needed to
386 improve the CKD prevalence estimates and to improve the precision of the pooled estimate. Better
387 reporting is also needed to detail the methods used and to disaggregate CKD prevalence by age to
388 isolate the most affected age groups. The moderately high CKD prevalence implies that HIV control
389 programs need to routinely screen YPLHIV for CKD to ensure early diagnosis and management
390 hence improving survival and quality of life in this young population.

391 **Acknowledgments**

392 The authors would like to acknowledge James Prior for the support to EMN and the Librarian at
393 LSHTM, Kate Perris who helped with the development and review of the search terms. Support for
394 research was provided by Fogarty International Centre, National Institutes of Health (grant
395 #2D43TW009771-06) HIV and co-infections in Uganda. HAW is funded by the UK Medical
396 Research Council (MRC) and the UK Department for International Development (DFID) under the
397 MRC/DFID Concordat agreement (Grant Ref: MR/R010161/1). EN, Doctoral Research Fellow,
398 NIHR131273 is funded by the NIHR for this research project. The views expressed in this publication
399 are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health
400 and Social Care.

401

402 **References**

- 403 1. UNAIDS. Young People and HIV: UNAIDS; 2021 [Available from:
404 https://www.unaids.org/sites/default/files/media_asset/young-people-and-hiv_en.pdf.
- 405 2. UNFPA. UNFPA SUPPORT TO THE HIV RESPONSE – AN OVERVIEW (2016 to 2019)
406 Geneva: United Nations 2020 [Available from: [https://www.unfpa.org/sites/default/files/admin-](https://www.unfpa.org/sites/default/files/admin-resource/HIV_Eval_Report_FINAL.pdf)
407 [resource/HIV_Eval_Report_FINAL.pdf](https://www.unfpa.org/sites/default/files/admin-resource/HIV_Eval_Report_FINAL.pdf).
- 408 3. UNAIDS. AIDSInfo: Global data on HIV epidemiology and response Geneva: UNAIDS;
409 2023 [Available from: <https://aidsinfo.unaids.org/>.
- 410 4. Davies M-A, Gibb D, Turkova A. Survival of HIV-1 vertically infected children. Current
411 opinion in HIV and AIDS. 2016;11(5):455-64.
- 412 5. Innes S, Patel K. Non-communicable diseases in adolescents with perinatally-acquired HIV-1
413 infection in high-and low-income settings. Current opinion in HIV and AIDS. 2018;13(3):187.
- 414 6. Frigati LJ, Brown K, Mahtab S, Githinji L, Gray D, Zuhlke L, et al. Multisystem impairment
415 in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART). Journal
416 of the International AIDS Society. 2019;22(8):e25386.
- 417 7. Slogrove AL, Mahy M, Armstrong A, Davies MA. Living and dying to be counted: What we
418 know about the epidemiology of the global adolescent HIV epidemic. Journal of the International
419 AIDS Society. 2017;20:21520.
- 420 8. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. HIV Infection in Children and
421 Adolescents. Cham: Springer International Publishing; 2020. p. 143-52.
- 422 9. Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities
423 in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of
424 antiretroviral therapy. The Lancet Child and Adolescent Health. 2020;4(9):688-98.

- 425 10. Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. *Nature reviews*
426 *Nephrology*. 2009;5(10):591-8.
- 427 11. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney International*
428 *Supplements*. 2022;12(1):7-11.
- 429 12. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al.
430 Nomenclature for kidney function and disease: executive summary and glossary from a *Kidney*
431 *Disease: Improving Global Outcomes (KDIGO) consensus conference*. *Kidney Diseases*.
432 2020;6(5):309-17.
- 433 13. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. *The Lancet*.
434 2017;389(10075):1238-52.
- 435 14. Burniston M. Clinical guideline for the measurement of glomerular filtration rate (GFR) using
436 plasma sampling. *British Nuclear Medicine Society*; 2018. 2020.
- 437 15. Carrara F, Gaspari F. GFR measured by iohexol: the best choice from a laboratory
438 perspective. *Journal of Laboratory and Precision Medicine*. 2018;3.
- 439 16. Levey AS, Inker LA, Coresh J. GFR Estimation: From Physiology to Public Health.
440 *American Journal of Kidney Diseases*. 2014;63(5):820-34.
- 441 17. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
442 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of
443 Disease Study 2017. *The lancet*. 2020;395(10225):709-33.
- 444 18. Charles C, Ferris AH. Chronic Kidney Disease. *Primary Care: Clinics in Office Practice*.
445 2020;47(4):585-95.

- 446 19. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, et al. The epidemiology of
447 chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. *The Lancet*
448 *Global Health*. 2014;2(3):e174-e81.
- 449 20. Fabian J. Chronic kidney disease in HIV infection: early detection and preventive strategies.
450 *Continuing Medical Education*. 2007;25(8).
- 451 21. Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV-related chronic
452 kidney disease in the era of antiretroviral therapy. *Kidney International*. 2014;86(2):259-65.
- 453 22. Ross MJ. Advances in the pathogenesis of HIV-associated kidney diseases. *Kidney*
454 *International*. 2014;86(2):266-74.
- 455 23. Wyatt CM. Kidney disease and HIV infection. *Topics in antiviral medicine*. 2017;25(1):13.
- 456 24. Fiseha T, Gebreweld A. Renal function in a cohort of HIV-infected patients initiating
457 antiretroviral therapy in an outpatient setting in Ethiopia. *PloS one*. 2021;16(1):e0245500.
- 458 25. Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive
459 patients with varying degrees of proteinuria in South Africa. *Kidney international*. 2006;69(12):2243-
460 50.
- 461 26. Baynes HW, Tegene B, Gebremichael M, Birhane G, Kedir W, Biadgo B. Assessment of the
462 effect of antiretroviral therapy on renal and liver functions among hiv-infected patients: A
463 retrospective study. *HIV/AIDS - Research and Palliative Care*. 2017;9:1-7.
- 464 27. Purswani MU, Chernoff MC, Mitchell CD, Seage GR, Zilleruelo G, Abitbol C, et al. Chronic
465 kidney disease associated with perinatal HIV infection in children and adolescents. *Pediatric*
466 *nephrology*. 2012;27(6):981-9.
- 467 28. Kaspar C, Bholah R, Bunchman T. A review of pediatric chronic kidney disease. *Blood*
468 *purification*. 2016;41(1-3):211-7.

- 469 29. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal
470 HIV-1 infection. *Journal of the International AIDS Society*. 2013;16(1):18596.
- 471 30. Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children.
472 *Advances in chronic kidney disease*. 2017;24(6):348-56.
- 473 31. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C
474 versus creatinine in determining risk based on kidney function. *New England Journal of Medicine*.
475 2013;369(10):932-43.
- 476 32. Delanaye P, Ebert N. Estimating GFR in children. *Nature Reviews Nephrology*.
477 2012;8(9):503-4.
- 478 33. Frigati L, Mahtab S, Nourse P, Ray P, Perrazzo S, Machededze T, et al. Prevalence of risk
479 factors for chronic kidney disease in South African youth with perinatally acquired HIV. *Pediatric*
480 *nephrology (Berlin, Germany)*. 2018;34(2):313-8.
- 481 34. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
482 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *International Journal*
483 *of Surgery*. 2021;88:105906.
- 484 35. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
485 systematic reviews. *Systematic reviews*. 2016;5(1):1-10.
- 486 36. JBI. Checklist for Prevalence Studies Adelaide: Univeristy of Adelaide; 2020 [Available
487 from: <https://jbi.global/critical-appraisal-tools>.
- 488 37. George PP, DeCastro Molina JA, Heng BH. The methodological quality of systematic
489 reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular
490 degeneration: A systematic review of reviews. *Indian J Ophthalmol*. 2014;62(7):761-7.

- 491 38. Lin L, Xu C. Arcsine-based transformations for meta-analysis of proportions: Pros, cons, and
492 alternatives. *Health Sci Rep.* 2020;3(3):e178.
- 493 39. Linares-Espinós E, Hernández V, Domínguez-Escrig JL, Fernández-Pello S, Hevia V, Mayor
494 J, et al. Methodology of a systematic review. *Actas urológicas españolas.* 2018;42(8):499-506.
- 495 40. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al.
496 Meta-analysis of prevalence: I² statistic and how to deal with heterogeneity. *Research synthesis*
497 *methods.* 2022;13(3):363-7.
- 498 41. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to
499 detect publication bias in meta-analysis. *Jama.* 2006;295(6):676-80.
- 500 42. Martens H, Martens M. Modified Jack-knife estimation of parameter uncertainty in bilinear
501 modelling by partial least squares regression (PLSR). *Food quality and preference.* 2000;11(1-2):5-16.
- 502 43. IOM (Institute of Medicine). Finding what works in health care: standards for systematic
503 reviews. Washington, DC: The National Academies Press.; 2011.
- 504 44. Iduoriyekemwen NJ, Sadoh WE, Sadoh AE. Prevalence of renal disease in Nigerian children
505 infected with the human immunodeficiency virus and on highly active anti-retroviral therapy. *Saudi*
506 *journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ*
507 *Transplantation, Saudi Arabia.* 2013;24(1):172-7.
- 508 45. Diack A, Yonaba C, Coulibaly A, Ouedraogo S, Penda I, Bukuru H, et al. Progressive
509 Decline of the Glomerular Filtration Rate in HIV-infected Children Treated With Tenofovir
510 Disoproxil Fumarate-based Regimens in West and Central Africa. *The Pediatric infectious disease*
511 *journal.* 2020;39(8):737-9.
- 512 46. Okafor UH, Unuigbo EI, Chukwuonye E. Prevalence and clinical and laboratory
513 characteristics of kidney disease in anti-retroviral-naive human immunodeficiency virus-infected

- 514 patients in South-South Nigeria. Saudi journal of kidney diseases and transplantation : an official
515 publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2016;27(1):129-34.
- 516 47. Byers BW, Drak D, Shamu T, Chimbetete C, Dahwa R, Gracey DM. Assessing renal
517 impairment in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in
518 Zimbabwe. AIDS. 2023;37(5):789-94.
- 519 48. Lomole AP, Macharia WM, Limbe MS, Kinuthia DW, Kabinga SK. Estimation of Burden of
520 Kidney Dysfunction in HIV-infected Pediatrics and Adolescents by Use of Urinary Neutrophil
521 Gelatinase-Associated Lipocalin: A Single Center Experience in Kenya. Infectious Diseases &
522 Immunity. 2021;1:E004-E.
- 523 49. Mosten IK, Hamel BC, Kinabo GD. Prevalence of persistent microalbuminuria and associated
524 factors among HIV infected children attending a Tertiary Hospital in Northern Tanzania: a cross
525 sectional, analytical study. The Pan African medical journal. 2015;20:251.
- 526 50. Fredrick F, Francis JM, Ruggajo PJ, Maro EE. Renal abnormalities among HIV infected
527 children at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania. BMC nephrology.
528 2016;17:30.
- 529 51. Tadesse BT, Foster BA, Kabeta A, Ayalew F, H/Meskel G, Jerene D, et al. Hepatic and renal
530 toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective
531 cohort study. HIV medicine. 2019;20(2):147-56.
- 532 52. Bagoloire LK, Sheilla A, Kalyango J, Mugerwa H, Bruhan K, Waiswa P, et al. Prevalence
533 and Factors Associated with Renal Disease Among HIV Infected Children on Antiretroviral Therapy
534 Attending Joint Clinical Research Center, Lubowa, Kampala. medRxiv. 2023.
- 535 53. Mashingaidze-Mano R, Bwakura-Dangarembizi MF, Maponga CC, Morse GD, Monera-
536 Penduka TG, Mtisi TJ, et al. Proximal renal tubular function in HIV-infected children on tenofovir

- 537 disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
538 PloS one. 2020;15(7):e0235759.
- 539 54. Drak D, Dahwa R, Reakes E, Heron JE, Shamu T, Chimbetete C, et al. Baseline renal
540 function predicts mortality in adolescents commenced on HIV antiretroviral therapy. AIDS.
541 2021;35(5):843-5.
- 542 55. Zimba KM. Prevalence and factors associated with renal dysfunction in HIV positive
543 paediatric patients on highly active antiretroviral therapy at the paediatric centre of excellence of the
544 university teaching hospital, in Lusaka, Zambia. Pediatric Nephrology. 2016;31(10):1778.
- 545 56. Areprekumor T-e, Kelechi O, Peterside O. Prevalence of Microalbuminuria and Associated
546 Risk Factors in HIV-Infected Children seen at a Tertiary Health Centre in the Niger Delta Region of
547 Nigeria. Areprekumor, T-ebi, Kelechi, O, & Peterside, O(2023) Prevalence of Microalbuminuria and
548 Associated Risk Factors in HIV-Infected Children seen at a Tertiary Health Centre in the Niger Delta
549 Region of Nigeria Journal of Advances in Medicine and Medical Research. 2023;35(24):23-34.
- 550 57. Ekulu PM, Nkoy AB, Betukumesu DK, Aloni MN, Makulo JRR, Sumaili EK, et al. APOL1
551 Risk Genotypes Are Associated With Early Kidney Damage in Children in Sub-Saharan Africa.
552 Kidney international reports. 2019;4(7):930-8.
- 553 58. Drak D, Shamu T, Heron JE, Chimbetete C, Dahwa R, Gracey DM. Renal function and
554 associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe. AIDS
555 (London, England). 2022;36(5):631-6.
- 556 59. Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney
557 disease in the global adult HIV-infected population: a systematic review and meta-analysis. PloS one.
558 2018;13(4):e0195443.

- 559 60. Park J, Zuniga JA. Chronic Kidney Disease in Persons Living with HIV: A Systematic
560 Review. *JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE*.
561 2018;29(5):655-66.
- 562 61. Abd ElHafeez S, Bolignano D, D'Arrigo G, Dounousi E, Tripepi G, Zoccali C. Prevalence
563 and burden of chronic kidney disease among the general population and high-risk groups in Africa: a
564 systematic review. *BMJ open*. 2018;8(1):e015069-e.
- 565 62. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global
566 prevalence of chronic kidney disease—a systematic review and meta-analysis. *PloS one*.
567 2016;11(7):e0158765.
- 568 63. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low-and middle-income
569 countries. *Nephrology Dialysis Transplantation*. 2016;31(6):868-74.
- 570 64. Triep K, Leichtle AB, Meister M, Fiedler GM, Endrich O. Real-world Health Data and
571 Precision for the Diagnosis of Acute Kidney Injury, Acute-on-Chronic Kidney Disease, and Chronic
572 Kidney Disease: Observational Study. *JMIR Med Inform*. 2022;10(1):e31356-e.
- 573 65. Bökenkamp A. Proteinuria—take a closer look! *Pediatric Nephrology*. 2020;35(4):533-41.
- 574 66. Bukabau JB, Yayo E, Gnionsahé A, Monnet D, Pottel H, Cavalier E, et al. Performance of
575 creatinine-or cystatin C–based equations to estimate glomerular filtration rate in sub-Saharan African
576 populations. *Kidney international*. 2019;95(5):1181-9.
- 577 67. Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D, Musenge E, et al.
578 Measurement of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study.
579 *The Lancet Global Health*. 2022;10(8):e1159-e69.
- 580 68. Bukabau JB, Sumaili EK, Cavalier E, Pottel H, Kifakiou B, Nkodila A, et al. Performance of
581 glomerular filtration rate estimation equations in Congolese healthy adults: the inopportunity of the
582 ethnic correction. *PloS one*. 2018;13(3):e0193384.

- 583 69. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating
584 glomerular filtration rate from serum creatinine and cystatin C. *New England Journal of Medicine*.
585 2012;367(1):20-9.
- 586 70. Kalyesubula R, Fabian J, Nakanga W, Newton R, Ssebunnya B, Prynne J, et al. How to
587 estimate glomerular filtration rate in sub-Saharan Africa: design and methods of the African Research
588 into Kidney Diseases (ARK) study. *BMC nephrology*. 2020;21(1):1-12.
- 589 71. Będzichowska A, Jobs K, Kloc M, Bujnowska A, Kalicki B. The Assessment of the
590 Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children. *Biomarker*
591 *insights*. 2021;16:11772719211011173.
- 592 72. Fabian J, George JA, Etheredge HR, van Deventer M, Kalyesubula R, Wade AN, et al.
593 Methods and reporting of kidney function: a systematic review of studies from sub-Saharan Africa.
594 *Clinical Kidney Journal*. 2019;12(6):778-87.
- 595 73. Dondo V, Mujuru HA, Nathoo KJ, Chirehwa M, Mufandaedza Z. Renal abnormalities among
596 HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study. 2013. p. 75-.
- 597 74. Eke FU, Anochie IC, Okpere AN, Eneh AU, Ugwu RO, Ejilemele AA, et al.
598 Microalbuminuria in children with human immunodeficiency virus (HIV) infection in Port Harcourt,
599 Nigeria. *Nigerian journal of medicine : journal of the National Association of Resident Doctors of*
600 *Nigeria*. 2010;19(3):298-301.
- 601 75. Esezobor CI, Iroha E, Oladipo O, Onifade E, Soriyan OO, Akinsulie AO, et al. Kidney
602 function of HIV-infected children in Lagos, Nigeria: using Filler's serum cystatin C-based formula.
603 *Journal of the International AIDS Society*. 2010;13:17.

604

605 **Supporting Information**

606 S1 Appendix 1: PRISMA checklist

607 S2 Appendix 2: Study Protocol

608 S3 Appendix 3 Search Strategy

609 S4 Appendix 4 Details of the included studies

610

Table 1: Details of the included Studies

First author, year	Country	Region	Population	Study design	Age (years)	% Female	Sample size	Prevalence % (95% CI)	Disease definition /diagnosis
Diack 2020	Burkina Faso, Côte d'Ivoire, Burundi, Senegal, Mali and Cameroon	Central and Western	0-18 years on TDF for 1.5 years	Cross sectional	Median 15.5 (IQR 14-16.8)	51	358	4.1 (2-7)	eGFR 30-60 ml/min/1.73m ²
Okafor 2016	South Nigeria	Western	ART naïve 18-81 years	Cross sectional	18-29 yrs	58	96	53.1 (43-63)	eGFR <60 mL/min/1.73m ²
Ekulu 2019	Democratic Republic of Congo	Central	<18 years on ART	Cross sectional	Mean 11.6 (SD 4.1)	51	401	6.5 (4-9)	eGFR <60ml/min/1.73m ²
Frigati 2019	South Africa	Southern	Perinatally infected 9-14 years on ART > 6 months	Cross sectional	Mean 12 (SD 1.7)	48	384	2.3 (1.1-4.4)	eGFR<90 mL/min/1.73m ²
Frederick 2016	Tanzania	Eastern	Both ART naïve and on ART	Cross sectional	10-14 yrs	44.6	86	22.1 (13.9-2.3)	ACR ≥30 mg/g
Frigati 2018	South Africa	Southern	9-14 years on ART > 6 months	Cross sectional	9-14 yrs	48.7	511	8.4 (6.1-11.2)	ACR >30mg/g
Iduoriyekemwen, 2013	Nigeria	Western	10 months to 17 years on ART	Cross sectional	12-17yrs	40	12	16.7 (2- 48)	Proteinuria 1+ microalbuminuria of ≥20 mg/g eGFR <60ml/min/1.73m ²
Mashingaidze-Mano, 2020	Zimbabwe	Southern	<18 years on TDF for >6 months	Cross sectional	Median 15 (IQR 13-16)	44.9	198	35.9 (29-43)	eGFR<90ml/min/1.73m ²
Drak, 2021	Zimbabwe	Southern	ART naïve 12-17 years	Cross sectional	Median 14.3 (IQR 14.1-14.5)	55	282	13.1% (9-17.6)	eGFR<90ml/min/1.73m ²
							209	7.2 (4-11.4)	Proteinuria of 1+
Lomole 2021	Kenya	Eastern	3-18 years on ART	Cross sectional	Mean 11.9 (SD 3.6)	49.5	93	15.1 (8.4-24)	UNGAL

Tadesse 2019	Ethiopia	Eastern	Perinatally HIV+ < 18 years on ART for > 6 months	Cohort	Median 12 years (IQR 8-14)	46.7	784	0.8 (0.2-1)	eGFR60-90ml/min/1.73m ²
Mosten 2015	Tanzania	Eastern	HIV+ below 18 years.	Cross sectional	Mean 10 years (4-18)	44.8	330	28.8 (23.9-34)	Microalbuminuria 20 - 200 mg/L
Zimba 2015	Zambia	Southern	HIV+ 18 months to 16 years on ART	Cross sectional	Mean 9.3 years (SD 3.84)	50.2	209	3.8 (1.7-7.4)	eGFR<60ml/min/1.73m ²
							209	8.1 (4.8-12.7)	Proteinuria of 1+
Bagoloire 2023	Uganda	Eastern	HIV+ 3-17 years on ART	Cross sectional	Mean 12.0 (SD 3.21)	51.0	205	10.2 (6.8-15.2)	eGFR<60ml/min/1.73m ²
Areprekumor 2023	Nigeria	Western	HIV+	Cross sectional	11-18yrs	50.7	150	28.1 (17.5-40.8)	Microalbuminuria
Byers 2023	Zimbabwe	Southern	HIV+ ART naive	Cohort	12-17 years	55	266	3.8 (1.8-6.8)	eGFR60-90ml/min/1.73m ²




Figure 1 : PRISMA flow chart showing the review process and included studies




Figure 2: Forest Plot of the included studies




Figure 3: Funnel Plot of included studies